[go: up one dir, main page]

WO2005033334A3 - Verfahren zur bestimmung einer wirkstoffdosierung - Google Patents

Verfahren zur bestimmung einer wirkstoffdosierung Download PDF

Info

Publication number
WO2005033334A3
WO2005033334A3 PCT/EP2004/010560 EP2004010560W WO2005033334A3 WO 2005033334 A3 WO2005033334 A3 WO 2005033334A3 EP 2004010560 W EP2004010560 W EP 2004010560W WO 2005033334 A3 WO2005033334 A3 WO 2005033334A3
Authority
WO
WIPO (PCT)
Prior art keywords
specific
active ingredient
genetic
data
pbpk model
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/010560
Other languages
English (en)
French (fr)
Other versions
WO2005033334A2 (de
Inventor
Walter Schmitt
Stefan Willmann
Edgar Diessel
Ingmar Dorn
Jens Burmeister
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Technology Services GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Technology Services GmbH filed Critical Bayer Technology Services GmbH
Priority to AU2004278478A priority Critical patent/AU2004278478A1/en
Priority to EP04765437A priority patent/EP1671250A2/de
Priority to CA002540789A priority patent/CA2540789A1/en
Priority to JP2006529998A priority patent/JP2007510970A/ja
Publication of WO2005033334A2 publication Critical patent/WO2005033334A2/de
Publication of WO2005033334A3 publication Critical patent/WO2005033334A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Evolutionary Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Es wird ein Verfahren zur Bestimmung der Dosierung von mindestens einem Wirkstoff auf Basis einer genetischen Analyse beschrieben. Das Verfahren umfasst die folgenden Schritte: a) Analyse (101) von spezifischen Gensequenzen, mittels eines gensequenz-spezifischen Analysengerätes, insbesondere eines sequenz-spezifischen Sensors, oder Bestimmung der Expression von Proteinen entweder über RNA Transkription mittels quantitativer RNA-spezifischer Nachweismethoden oder direkte Messung der Proteinexpression durch ein Protein-Analysegerät b) Zuordnung der Gensequenzen zu physiologischen Funktionen des menschlichen oder tierischen Körpers, insbesondere solchen physiologischen Funktionen, die Einfluss auf den Abbau, auf die Aufnahme, auf die Abgabe oder auf das Verteilungsverhalten des Wirkstoffes im Körper haben, c) Weitergabe der genetischen und der Zuordnungsdaten an einen physiologie-basiertes Pharmakokinetisches Modell (PBPK-Modell) (108), d) Eingabe von Wirkstoff-spezifischen Daten in das PBPK-Modell (108), e) Eingabe von charakteristischen Patientendaten, gegebenenfalls aus direkten Messungen am Körper , f) Berechnung von für das PBPK-Modell notwendigen physiologischen Einflussparametern aus den Patientendaten unter Verwendung von in der Wissensdatenbank enthaltenen Informationen und Weitergabe der Parameter an das PBPK-Modell (108), g) Berechnung der individuellen Dosis aus den Daten nach den Schritten c), d) und f) unter Verwendung des PBPK-Modells (108).
PCT/EP2004/010560 2003-10-02 2004-09-21 Verfahren zur bestimmung einer wirkstoffdosierung Ceased WO2005033334A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2004278478A AU2004278478A1 (en) 2003-10-02 2004-09-21 Method for determining an active ingredient dosage
EP04765437A EP1671250A2 (de) 2003-10-02 2004-09-21 Verfahren zur bestimmung einer wirkstoffdosierung
CA002540789A CA2540789A1 (en) 2003-10-02 2004-09-21 Method for determining an active ingredient dosage
JP2006529998A JP2007510970A (ja) 2003-10-02 2004-09-21 活性物質の投与量の決定方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10345837.9 2003-10-02
DE10345837A DE10345837A1 (de) 2003-10-02 2003-10-02 Verfahren zur Bestimmung einer Wirkstoffdosierung

Publications (2)

Publication Number Publication Date
WO2005033334A2 WO2005033334A2 (de) 2005-04-14
WO2005033334A3 true WO2005033334A3 (de) 2005-09-29

Family

ID=34353270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/010560 Ceased WO2005033334A2 (de) 2003-10-02 2004-09-21 Verfahren zur bestimmung einer wirkstoffdosierung

Country Status (7)

Country Link
US (1) US20050074803A1 (de)
EP (1) EP1671250A2 (de)
JP (1) JP2007510970A (de)
AU (1) AU2004278478A1 (de)
CA (1) CA2540789A1 (de)
DE (1) DE10345837A1 (de)
WO (1) WO2005033334A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8949032B2 (en) * 2002-03-29 2015-02-03 Genomatica, Inc. Multicellular metabolic models and methods
DE102004010516A1 (de) 2004-03-04 2005-09-22 Bayer Technology Services Gmbh Verbessertes Verfahren zur zeitlichen Dosierung von Arzneistoffen
DE102005028080A1 (de) 2005-06-17 2006-12-21 Bayer Technology Services Gmbh Verfahren zur zeitlich gesteuerten intravenösen Verabreichung des Narkosemittels Propofol
EP3223182A1 (de) * 2005-11-29 2017-09-27 Children's Hospital Medical Center Optimierung und individualisierung von medikamentenauswahl und -dosierung
JP2007279999A (ja) * 2006-04-06 2007-10-25 Hitachi Ltd 薬物動態解析システム及び方法
DE102006028232A1 (de) * 2006-06-20 2007-12-27 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis
JP5227189B2 (ja) * 2006-12-27 2013-07-03 株式会社根本杏林堂 薬液注入装置および薬液注入方法
US20080221847A1 (en) * 2007-03-09 2008-09-11 Frederique Fenetteau Method of developing a pharmacokinetic profile of a xenobiotic disposition in a mammalian tissue
WO2009104110A1 (en) * 2008-02-18 2009-08-27 Koninklijke Philips Electronics N.V. Administration of drugs to a patient
US20100125782A1 (en) * 2008-11-14 2010-05-20 Howard Jay Snortland Electronic document for automatically determining a dosage for a treatment
US20100125421A1 (en) * 2008-11-14 2010-05-20 Howard Jay Snortland System and method for determining a dosage for a treatment
EP2538360A1 (de) * 2011-06-16 2012-12-26 Koninklijke Philips Electronics N.V. Verfahren zur Vorhersage eines Blutverdünnungsrisikowerts
JP6483681B2 (ja) * 2013-07-29 2019-03-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 刺激を動的に変化させるリアルタイムフィードバックシステム制御技術プラットホーム
WO2015017798A2 (en) 2013-08-02 2015-02-05 CRIXlabs, Inc. Method and system for predicting spatial and temporal distributions of therapeutic substance carriers
EP3236956A1 (de) 2014-12-23 2017-11-01 Bosteels, Arnaud Kombination von remifentanil und propofol
US10854326B2 (en) * 2017-11-21 2020-12-01 Verisim Life Inc. Systems and methods for full body circulation and drug concentration prediction
CN113140321B (zh) * 2021-05-20 2023-12-19 中国药科大学 运用PK-sim预测异甘草酸镁在人体中暴露浓度的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
AUPR446701A0 (en) * 2001-04-18 2001-05-17 Gene Stream Pty Ltd Transgenic mammals for pharmacological and toxicological studies
US20030104428A1 (en) * 2001-06-21 2003-06-05 President And Fellows Of Harvard College Method for characterization of nucleic acid molecules

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOGAARDS J J P ET AL: "Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 2000 NETHERLANDS, vol. 12, no. 2, 2000, pages 117 - 124, XP002339733, ISSN: 0928-0987 *
DOOLEY T P ET AL: "A method to improve selection of molecular targets by circumventing the ADME pharmacokinetic system utilizing PharmArray DNA microarrays", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 303, 11 April 2003 (2003-04-11), pages 828 - 841, XP002982396, ISSN: 0006-291X *
EVANS W E ET AL: "Pharmacogenomics - Drug disposition, drug targets, and side effects", NEW ENGLAND JOURNAL OF MEDICINE 06 FEB 2003 UNITED STATES, vol. 348, no. 6, 6 February 2003 (2003-02-06), pages 538 - 549, XP002339735, ISSN: 0028-4793 *
LIPSCOMB J C ET AL: "Incorporating human interindividual biotransformation variance in health risk assessment", SCIENCE OF THE TOTAL ENVIRONMENT 08 APR 2002 NETHERLANDS, vol. 288, no. 1-2, 8 April 2002 (2002-04-08), pages 13 - 21, XP002339734, ISSN: 0048-9697 *
SARANGAPANI R ET AL: "Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of vapors", INHALATION TOXICOLOGY 2003 UNITED STATES, vol. 15, no. 10, 1 September 2003 (2003-09-01), pages 987 - 1016, XP009051815, ISSN: 0895-8378 *

Also Published As

Publication number Publication date
DE10345837A1 (de) 2005-04-21
JP2007510970A (ja) 2007-04-26
EP1671250A2 (de) 2006-06-21
US20050074803A1 (en) 2005-04-07
AU2004278478A1 (en) 2005-04-14
WO2005033334A2 (de) 2005-04-14
CA2540789A1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
WO2005033334A3 (de) Verfahren zur bestimmung einer wirkstoffdosierung
WO2003004696A3 (en) A distributed system for epigenetic based prediction of complex phenotypes
WO2006069677A3 (en) Combination comprising an agent providing a signal, an implant material and a drug
WO2003047428A3 (en) Apparatus and methods for testing pain sensitivity
ATE361024T1 (de) Vorrichtung und verfahren zur bestimmung des analytpegels
WO2006085146A3 (en) System for continuous outcome prediction during a clinical trial
EP1236434A3 (de) Anordnung und Verfahren zur Herzschlagüberwachung
JP2007510970A5 (de)
WO2005023086A3 (en) Systems, methods, and computer program products for analysis of vessel attributes for diagnosis, disease staging, and surgical planning
WO2005062770A3 (en) Method for conducting pharmacogenomics-based studies
IL163636A (en) Device, system and method for temperature sensing in an in-vivo device
EP1364666A8 (de) System zur kontrolle biologischer informationen und von informationen einer blutbehandlungsvorrichtung, vorrichtung zur kontrolle biologischer informationen und von informationen einer blutbehandlungsvorrichtung und methode zur kontrolle biologischer informationen und von informationen einer blutbehandlungsvorrichtung
WO2003066876A3 (en) An apparatus and methods for using biological material to discriminate an agent
WO2002057795A3 (en) Methods of diagnosis and treatment of osteoporosis
DE50212519D1 (de) Verfahren und vorrichtung zur messung des dynamischen verhaltens des auges
WO2004006854A3 (en) Method for identification of biologically active agents
CA2455455A1 (en) Method and system to determine revised dosage
WO2002063951A3 (en) Human disease modeling using somatic gene transfer
WO2008072275A3 (en) Telematic system for using diagnostic reagent strips and method for acquiring calibration data
WO2004113574A3 (en) Methods for disease screening
WO2002070741A3 (en) Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna
DE60234440D1 (de) Mdr1-varianten und verfahren zu ihrer verwendung
WO2007121319A3 (en) Compostions and methods for determining and predicting treatment responses for depression and anxiety
ATE446788T1 (de) Implantierbare medizinische vorrichtung, insebesondere zur stimulation, resynchronisierung,defibrillation, und/oder cardioversion mit diagnostischen mitteln zur vorhersage des klinischen zustands des patienten
WO2007103303A3 (en) Systems and methods using a dynamic expert system to provide patients with aesthetic improvement procedures

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004765437

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004278478

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2540789

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006529998

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004278478

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004765437

Country of ref document: EP